Stocktoria
Sino Biopharmaceutical Limited 1177.HK
HK · Hong Kong Stock Exchange · XHKG · stock · Healthcare · website
Sino Biopharmaceutical Limited financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | CN¥31.8B | CN¥28.9B | CN¥26.2B | CN¥26.0B |
| Gross profit | CN¥26.1B | CN¥23.5B | CN¥21.2B | CN¥21.5B |
| R&D expense | CN¥5.9B | CN¥5.1B | CN¥4.4B | CN¥4.2B |
| SG&A expense | CN¥13.1B | CN¥12.2B | CN¥11.1B | CN¥11.7B |
| Operating income | CN¥6.9B | CN¥6.3B | CN¥6.1B | CN¥5.5B |
| Interest expense | CN¥278.3M | CN¥295.1M | CN¥495.2M | CN¥429.5M |
| Income tax | CN¥1.6B | CN¥492.9M | CN¥797.3M | CN¥696.7M |
| Net income | CN¥2.3B | CN¥3.5B | CN¥2.3B | CN¥2.5B |
| EPS (diluted) | CN¥0.13 | CN¥0.19 | CN¥0.13 | CN¥0.12 |
| Operating cash flow | CN¥9.3B | CN¥6.6B | CN¥6.1B | CN¥6.3B |
| Free cash flow | CN¥7.6B | CN¥5.2B | CN¥4.4B | CN¥4.6B |
| Cash & equivalents | CN¥12.2B | CN¥9.6B | CN¥9.5B | CN¥12.1B |
| Inventory | CN¥2.3B | CN¥2.4B | CN¥2.0B | CN¥2.3B |
| Goodwill | CN¥3.5B | CN¥915.7M | CN¥680.5M | CN¥662.6M |
| Total assets | CN¥76.0B | CN¥65.4B | CN¥63.6B | CN¥64.1B |
| Total debt | CN¥16.1B | CN¥9.7B | CN¥12.6B | CN¥14.0B |
| Total liabilities | CN¥33.9B | CN¥22.6B | CN¥25.4B | CN¥26.1B |
| Shareholders' equity | CN¥30.7B | CN¥32.0B | CN¥30.5B | CN¥29.7B |
| Share buybacks | CN¥110.0M | CN¥1.3B | CN¥396.4M | CN¥867.6M |
Growth · year-over-year · Revenue CAGR 6.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +10.3% | +10.2% | +0.7% | — |
| Net income growth | -33.0% | +50.1% | -8.3% | — |
| EPS growth | -32.1% | +51.9% | +3.6% | — |
| Free cash flow growth | +45.4% | +19.7% | -4.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · HK · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.